Pharmacokinetic Studies Of Ciprofloxacin And Theophylline And Of The Interaction Between These Two Drugs In Healthy Malaysian Volunteers [RM301.5. A135 2007 f rb]. by Abdulla Alfadly, Saeed Obeid
PHARMACOKINETIC STUDIES OF CIPROFLOXACIN AND 
THEOPHYLLINE AND OF THE INTERACTION BETWEEN THESE 
TWO DRUGS IN HEALTHY MALAYSIAN VOLUNTEERS 
 
 
 
 
 
  
 
 
 
 
 
 
 
SAEED OBEID ABDULLA ALFADLY 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2007 
 
PHARMACOKINETIC STUDIES OF CIPROFLOXACIN AND THEOPHYLLINE 
AND OF THE INTERACTION BETWEEN THESE TWO DRUGS IN HEALTHY 
MALAYSIAN VOLUNTEERS 
 
 
 
 
 
 
 
BY 
 
 
 
 
 
 
 
SAEED OBEID ABDULLA ALFADLY 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements  
for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
September 2007 
 II
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my wife Jameela, my sons Abdulrahman and Ammar and my daughters 
Fatima and Suad and my brothers and sisters.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 III
ACKNOWLEDGEMENTS 
 
I would like to express my great heartfelt gratitude and thanks to Allah who 
bestowed on me the power and patience to complete my study. I also would like to 
express my sincere gratitude and deepest appreciation to my supervisor Associate 
Professor Dr. Yahya Hassan for his guidance, invaluable advices, unfailing support 
and encouragement throughout my study. I am also grateful to my co-supervisor 
Associate Professor Dr. Azmin Mohd Noor for his support, invaluable advices and 
his scientific guidance throughout the different sections of the study. 
 
My sincere thanks also go to Associate Professor Dr. Syed Azhar Syed 
Sulaiman (Dean of School of Pharmacy) and the Dean of the Institute of 
Postgraduate Studies for providing me good opportunity to finish my study in the 
field of Clinical Pharmacy. Many thanks and appreciation to all laboratory 
technicians and staff especially Mr. Chua Lian Siah, Tan Seow Pheng, Adam Ali, 
Fisal Jamaludin, Mohd Rizal, Rosli Kassim, Che Gayah Omar, Nuridah Ahamed 
and Srly who in one way or another have contributed in the success of this study. I 
am very thankful to all the volunteers for their participation and cooperation during 
the in-vivo studies.  
 
Finally, I am very grateful to the Benevolent Fund Foundation for 
outstanding students, Hadramout, Yemen for their financial support to pursue my 
study. My great thanks also go to the Ministry of Health, Yemen to provide me the 
opportunity to complete my study.  
 
 IV
CONTENTS 
           Page 
 
 
TITLE I 
DEDICATION II 
ACKNOWLEDGEMENTS III 
CONTENTS IV 
LIST OF TABLES XII 
LIST OF FIGURES XV 
LIST OF ABBREVIATIONS XVIII 
LIST OF EQUATIONS XX 
LIST OF APPENDICES XXI 
ABSTRAK XXIII
ABSTRACT 
 
XXVI
CHAPTER 1 : INTRODUCTION  1 
1.1 Principles of drug metabolism 1 
1.2 CYP enzymes  3 
 1.2.1  CYP1A subfamily 7 
 1.2.2  CYP2B6 8 
 1.2.3  CYP2C 9 
 1.2.4  CYP2D6 9 
 1.2.5  CYP2E1 10 
 1.2.6  CYP3A subfamily 10 
1.3 Inhibition of CYP enzymes  11 
1.4 Induction of CYP enzymes 13 
1.5 CYP inhibition and induction in drug-drug interactions  15 
1.6 Drug transporters 16 
1.7 Bioequivalence as a proof of therapeutic equivalence 18 
 1.7.1  Relative bioavailability 18 
 V
 1.7.2  Factors affecting bioavailability 20 
 1.7.3  Methodology used for the evaluation of 
          Bioequivalence 
 
23 
 1.7.4  Average bioequivalence 24 
1.8 General principles of reversed-phase HPLC for amphoteric and basic 
drugs 
 
28 
1.9 Development and validation of analysis method 33 
 1.9.1  Method development 34 
 1.9.2  Method validation 35 
           1.9.2.1  Selectivity 36 
           1.9.2.2  Calibration line 37 
           1.9.2.3  Recovery  38 
           1.9.2.4  Precision and accuracy 39 
           1.9.2.5  Limit of detection and limit of quantification 40 
           1.9.2.6  Stability of assay 40 
1.10 Drugs used in this study 42 
 1.10.1  Ciprofloxacin 42 
             1.10.1.1  Background  42 
             1.10.1.2  Ciprofloxacin chemistry 44 
             1.10.1.3  Ciprofloxacin pharmacokinetics 44 
             1.10.1.4  Ciprofloxacin adverse effects 46 
             1.10.1.5  HPLC assay of ciprofloxacin in plasma 47 
 1.10.2  Theophylline 51 
             1.10.2.1  Background 51 
             1.10.2.2  Theophylline pharmacokinetics 52 
 1.10.2.3 HPLC assay of theophylline in plasma 
                and its quantification with its metabolites 
                in urine 
 
55 
1.11 Justification of the study 
 
59 
1.12 Objectives of the present study 60 
 VI
CHAPTER 2 :  DETERMINATION OF CIPROFLOXACIN IN HUMAN  
                        PLASMA BY HIGH-PERFORMANCE LIQUID 
                        CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION 
 
62 
2.1 Introduction 62 
2.2 Materials and equipment 65 
2.3 Methods 67 
 2.3.1  Preparation of standards 67 
          2.3.1.1  Norfloxacin solution (internal standard) 67 
          2.3.1.2  Ciprofloxacin standards 67 
 2.3.2  Spectrophotometric measurement 68 
 2.3.3  Biological matrix 69 
 2.3.4  Analysis of ciprofloxacin by HPLC 69 
           2.3.4.1  Chromatographic system and conditions 69 
           2.3.4.2  Mobile phase composition 70 
           2.3.4.3  Sample preparation procedure 71 
           2.3.4.4  Determination of specificity/selectivity analysis 71 
           2.3.4.5  Determination of detector linearity 72 
           2.3.4.6  Preparation of standard calibration curve 72 
           2.3.4.7  Determination of recovery, intra-day and inter-day 
                       precision and accuracy 
73 
           2.3.4.8  Determination of the assay sensitivity  74 
           2.3.4.9  Determination of freeze and thaw cycle stability 75 
           2.3.4.10 Determination of drug stability in plasma samples 
                        on long storage    
75 
2.4 Results 76 
 2.4.1  Specificity/selectivity 76 
 2.4.2  Detector linearity 80 
 2.4.3  Standard calibration curve 80 
 2.4.4 Analytical recovery, intra-day and inter-day precision and 
accuracy  
            
83 
 VII
 2.4.5 Sensitivity of the assay 85 
 2.4.6 Freeze and thaw cycle stability study 87 
 2.4.7 Stability study on long storage 87 
 2.4.8 Application of assay method 88 
2.5 Discussion 91 
2.6 Conclusion 
 
95 
CHAPTER 3 : BIOEQUIVALENCE EVALUATION OF TWO DIFFERENT  
                       FORMULATIONS OF CIPROFLOXACIN TABLETS IN 
                       HEALTHY VOLUNTEERS 
96 
 
3.1 
 
Introduction 
 
96 
3.2 Materials and methods 98 
 3.2.1  Materials 98 
 3.2.2  In-vivo study protocol 99 
           3.2.2.1  Study subjects and ethical considerations 99 
           3.2.2.2  Clinical and safety records  102 
           3.2.2.3  Study design 102 
           3.2.2.4  Inclusion criteria for the volunteers 103 
             3.2.2.5  Exclusion criteria for the volunteers 103 
           3.2.2.6  Deviation from the study plan 104 
           3.2.2.7  Study performance and sample collection 104 
 3.2.3  Ciprofloxacin assay by HPLC 105 
 3.2.4  Pharmacokinetic parameters analysis 105 
 3.2.5  Statistical analysis 106 
3.3 Results 107 
 3.3.1  Safety and tolerability 107 
 3.3.2  Plasma ciprofloxacin analysis 107 
 3.3.3  Pharmacokinetic parameters 111 
3.4 Discussion 121 
3.5 Conclusion 128 
 
 
 VIII
CHAPTER 4 : HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC  
                       METHOD FOR THE DETERMINATION OF 
                       THEOPHYLLINE IN HUMAN PLASMA 
130 
 
4.1 
 
Introduction 
 
130 
4.2 Materials and apparatus 134 
4.3 Methods 136 
 4.3.1  Preparation of standard solutions  136 
           4.3.1.1  β-Hydroxyethyltheophylline (internal standard) 136 
           4.3.1.2  Theophylline (standard) 136 
 4.3.2  Spectrophotometric measurement 137 
 4.3.3  Biological matrix 138 
 4.3.4  Analysis of theophylline by HPLC 138 
           4.3.4.1  Chromatographic system and conditions 138 
           4.3.4.2  Mobile phase composition 138 
           4.3.4.3  Extraction procedure 139 
           4.3.4.4  Determination of specificity/selectivity analysis 139 
           4.3.4.5  Determination of detector linearity 140 
           4.3.4.6  Preparation of standard calibration curve 140 
           4.3.4.7  Determination of recovery, intra-day and inter-day 
                       precision and accuracy 
141 
           4.3.4.8  Determination of the assay sensitivity 142 
           4.3.4.9  Determination of freeze and thaw cycle stability 142 
           4.3.4.10  Determination of drug stability in plasma samples 142 
4.4 Results 143 
 4.4.1  Specificity/selectivity 143 
 4.4.2  Detector linearity 147 
 4.4.3  Standard calibration curve 147 
 4.4.4 Analytical recovery, intra-day and inter-day precision and 
accuracy  
150 
 4.4.5  Sensitivity of the assay 153 
 4.4.6  Freeze and thaw cycle stability study 155 
 IX
 4.4.7  Stability study in plasma samples  156 
4.5 Discussion 157 
4.6 Conclusion 162 
 
CHAPTER 5 : SIMULTANEOUS DETERMINATION OF THEOPHYLLINE 
                       AND ITS MAJOR METABOLITES IN HUMAN URINE BY 
                       REVERSED-PHASE ION PAIR ISOCRATIC HIGH-  
                       PERFORMANCE LIQUID CHROMATOGRAPHY 
 
163 
5.1 Introduction 163 
5.2 Materials and equipment 167 
5.3 Methods 169 
 5.3.1  Preparation of standard and buffer solutions 169 
           5.3.1.1  Theophylline standards 169 
           5.3.1.2  β-Hydroxyethyltheophylline  169 
 5.3.1.3  3-Methylxanthine, 1-Methyluric acid and 1,3- 
             Dimethyluric acid 
169 
           5.3.1.4  Carbonate buffer solution     170 
 5.3.2  Biological matrix 170 
 5.3.3  Analysis of theophylline and its major metabolites in urine 
          by HPLC 
170 
           5.3.3.1  Chromatographic system and conditions 170 
           5.3.3.2  Mobile phase composition 172 
           5.3.3.3  Sample extraction procedure 172 
           5.3.3.4  Determination of specificity/selectivity analysis  173 
           5.3.3.5  Determination of detector linearity 174 
           5.3.3.6  Preparation of standard calibration curve 174 
           5.3.3.7  Determination of recovery, intra-day and inter-day 
                       precision and accuracy 
175 
           5.3.3.8  Determination of the assay sensitivity 175 
 5.3.3.9  Determination of theophylline and its major  
             metabolites stability in urine samples 
176 
5.4 Results 176 
 X
 5.4.1  Specificity/selectivity  176 
 5.4.2  Detector linearity 179 
 5.4.3  Standard calibration curve 181 
 5.4.4  Analytical recovery, intra-day and inter-day precision and 
accuracy    
183 
 5.4.5  Sensitivity of the assay 187 
 5.4.6  Stability study 188 
5.5 Discussion 189 
5.6 Conclusion 196 
CHAPTER 6:  THE EFFECT OF MULTIPLE-DOSING OF CIPROFLOXACIN 
                        ON THE PHARMACOKINETICS OF THEOPHYLLINE IN  
                        HEALTHY VOLUNTEERS 
197 
 
6.1 
 
Introduction 
 
197 
6.2 Materials and methods 199 
 6.2.1  Materials 199 
 6.2.2  Study volunteers 199 
 6.2.3  Clinical and safety procedures 201 
 6.2.4  Study design 201 
 6.2.5  Inclusion criteria 202 
 6.2.6  Exclusion criteria 202 
 6.2.7  Restrictions on volunteers 203 
 6.2.8  Deviation from the study 203 
 6.2.9  Study performance and sample collection 203 
 6.2.10  Assay of ciprofloxacin in plasma by HPLC 204 
 6.2.11 Assay of theophylline in plasma and theophylline with its 
            metabolites in urine by HPLC 
205 
 6.2.12  Pharmacokinetic and statistical analysis 205 
6.3 Results 207 
 6.3.1  Safety 207 
 6.3.2  Plasma theophylline analysis 207 
 6.3.3  Analysis of urine theophylline and its metabolites  208 
 XI
 6.3.4  Plasma ciprofloxacin analysis 208 
 6.3.5  Pharmacokinetic parameters of theophylline 216 
6.4 Discussion 232 
6.5 Conclusion 
 
240 
CHAPTER 7:  SUMMARY AND GENERAL CONCLUSION 
 
242 
CHAPTER 8:  SUGGESTIONS FOR FURTHER STUDIES 250 
 
REFERENCES 253 
APPENDICES 284 
LIST OF PUBLICATIONS AND SEMINARS 313 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XII
LIST OF TABLES 
 
                Page 
            
1.1 Examples of substrates, inhibitors and inducers of the main hepatic 
drug-metabolising CYP enzymes 
 
6 
1.2 Summary of some of the published HPLC methods for ciprofloxacin 
determination in plasma 
 
50 
1.3 Summary of some of the published HPLC methods for theophylline 
determination in plasma  
 
56 
1.4 Summary of some of the published HPLC methods for theophylline 
and its metabolites determination in urine 
 
58 
2.1 Sources of standard compounds and reagents used in this study 65 
2.2 Equipment used in this study 66 
2.3 Different mobile phases used for ciprofloxacin and norfloxacin 
separation during method development 
 
79 
2.4 Recovery of ciprofloxacin from plasma (N = 6) 83 
2.5 Intra-day precision and accuracy of assay method (N=6) 84 
2.6 Inter-day precision and accuracy of assay method (N=6) 85 
2.7 Freeze and thaw cycle stability (N=4) 87 
2.8 Stability of ciprofloxacin in human plasma (N=6) 88 
3.1 Demographic data of the volunteers and sequence of treatment 100 
3.2 Two-way crossover design 103 
3.3 Between-batch precision and accuracy of quality control for 
ciprofloxacin analysis 
 
111 
3.4 Individual values of AUC0-t, AUCt-∞ and AUC0-∞ for volunteers 1 to 24 114 
3.5 Individual numerical values of Cmax and Tmax from Ciprobay® and 
Enoxin® 
   
115 
3.6 Percentage of extrapolated AUC values of volunteers 116 
3.7 ANOVA Table of Logarithmic Transformed AUC0-t Values   118 
3.8 ANOVA Table of Logarithmic Transformed AUC0-∞ Values   118 
3.9 ANOVA Table of Logarithmic Transformed Cmax Values   119 
 XIII
3.10 ANOVA Table of Logarithmic Transformed Cmax / AUC0-∞   Values   119 
3.11 Individual numerical values of Ke, t ½ and Cmax / AUC0-∞   from 
Ciprobay® and Enoxin® 
120 
4.1 Sources of chemicals and reagents used in this study 134 
4.2 Apparatus used in this study 135 
4.3 Recovery of theophylline from plasma (N = 6)  150 
4.4 Intra-day precision and accuracy of assay method (N=6) 152 
4.5 Inter-day precision and accuracy of assay method (N=6) 152 
4.6 Freeze and thaw cycle stability (N = 6) 155 
4.7 Stability of theophylline in human plasma 156 
5.1 Sources of chemicals and reagents used in this study 167 
5.2 Equipment used in this study 168 
5.3 Analytical recoveries of 1-MU, 3- MX, Theophylline and 1,3-DMU 
(N=6) 
 
183 
 
5.4 Intra-day precision and accuracy  assay of 1-MU, 3- MX,    
Theophylline and 1,3-DMU (N=6) 
 
185 
5.5 Inter-day precision and accuracy  assay of 1-MU, 3- MX, 
Theophylline and 1,3-DMU (N=6) 
 
186 
5.6 Stability of theophylline and its major metabolites in human  urine 188 
6.1 Demographic data of the volunteers and sequence of treatment 200 
6.2 Three-way crossover design 201 
6.3 In-study between-batch precision and accuracy of theophylline (N=9) 
 
212 
6.4 In-study between-batch precision and accuracy assay of 2.5 µg/mL 
for 1-MU, 3-MX, theophylline and 5µg/mL for 1,3-DMU (N=9) 
 
213 
6.5 In-study between-batch precision and accuracy assay of 5 µg/mL for 
1-MU, 3-MX, theophylline and 10 µg/mL for 1,3-DMU (N=9) 
 
214 
6.6 In-study between-batch precision and accuracy assay of 20 µg/mL 
for 1-MU, 3-MX, theophylline and 40 µg/mL for 1,3-DMU (N=9) 
 
215 
 XIV
6.7 Individual values of AUC0-t, AUC0-∞ and Cmax for after single dose of 
theophylline (250 mg) administered either alone or concomitantly 
with ciprofloxacin in healthy volunteers (N=9) 
 
218 
6.8 Individual values of CL/F and Vd after single dose of theophylline 
(250 mg) administered either alone or concomitantly with 
ciprofloxacin in healthy volunteers (N=9) 
 
219 
6.9 Individual values of t ½, Tmax and Ke  after single dose of theophylline 
(250 mg) administered either alone or concomitantly with 
ciprofloxacin in healthy volunteers (N=9) 
 
220 
6.10 Summary of theophylline pharmacokinetics in healthy volunteers 
after single oral dose of 250 mg theophylline alone and in 
combination with ciprobay® (N=9) 
 
227 
 
6.11 Forty-eight hour urine recovery of theophylline and its metabolites 
with and without concomitant ciprofloxacin treatment expressed as 
mmol (mean ± SD)  
 
229 
 
6.12 Effect of ciprofloxacin on the renal clearance (ml/min) of theophylline 
and formation clearances to its metabolites 
 
229 
6.13 Pharmacokinetic parameters after single and after the last of the six 
multiple doses of ciprofloxacin (500 mg twice daily) administration in 
nine healthy volunteers. Values are shown as mean ± SD  
230 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XV
LIST OF FIGURES 
Page 
                
1.1 General structure of quinolones. X= C; R= cyclopropyl, ethyl, 
fluoroethyl, methylamino, fluorophenyl group and thiazine or oxazine 
ring. R’ = piperazin-1-yl, 4-methylpiperazin-1-yl, 3- methylpiperazin-
1-yl; R’’=fluorine atom 
 
43 
1.2 Metabolic pathways of theophylline. Numbers in parentheses 
indicate percentages of urinary metabolites in adults  
 
54 
2.1 Chemical structures of ciprofloxacin and norfloxacin (the internal 
standard) 
 
64 
2.2 UV absorption spectrum of 10 µg/mL ciprofloxacin 68 
2.3 The HPLC system used 70 
2.4 Chromatogram of (A) blank plasma, and (B) blank plasma spiked 
with the internal standard norfloxacin (1) and ciprofloxacin (2) (500 
ng/mL) 
 
77 
2.5 Chromatogram of aqueous solution of internal standard norfloxacin 
(peak 1) and ciprofloxacin (500 ng/mL) (peak 2) 
 
78 
2.6 Detector linearity for ciprofloxacin HCl 81 
2.7 Mean standard calibration curve of Ciprofloxacin HCl 82 
2.8 A chromatogram for the limit of quantification of ciprofloxacin 50 
ng/ml: peak (1) the internal standard norfloxacin; peak (2) 
ciprofloxacin 
 
86 
2.9 Chromatograms of processed plasma samples obtained from a 
healthy volunteer (A) 1.5 hr and (B) 2.5 hr after the oral 
administration of 500 mg of ciprofloxacin. Peak 1, norfloxacin 
(internal standard); Peak 2 ciprofloxacin 
 
89 
2.10 Concentration versus time curve profile of ciprofloxacin of a healthy 
human volunteer who was given a single oral dose of 500 mg of 
ciprofloxacin 
 
90 
3.1 Typical HPLC chromatogram blank of plasma 108 
3.2 Typical HPLC chromatograms of plasma samples of a volunteer after 
administration of the test preparation sampled at A: 0 hr and B: 0.75 
hr (peak 1 internal standard; peak 2 ciprofloxacin) 
 
109 
3.3 Typical HPLC chromatograms of plasma samples of the volunteers 
given the test product sampled at A: 0.25 hr and B: 24 hr 
 
110 
 XVI
3.4 Mean plasma ciprofloxacin concentration versus time profiles of 
Ciprobay® and Enoxin®. Mean ± SD, N=24 
  
113 
4.1 Chemical structures of theophylline and β-hydroxyethyltheophylline 133 
4.2 UV spectrum of 10 µg/mL theophylline solution 137 
4.3 Chromatogram of (A) blank plasma, and (B) blank plasma spiked 
with the internal standard β-hydroxyethyltheophylline 
 
144 
4.4 Chromatogram of blank plasma spiked with theophylline (2500 
ng/mL) (1) and the internal standard β-hydroxyethyltheophylline (2) 
 
145 
4.5 Chromatogram of aqueous solution of theophylline (1000 ng/mL) 
(peak 1) and internal standard β-hydroxyethyltheophylline (peak 2) 
 
146 
4.6 Detector linearity for theophylline 148 
4.7 Standard calibration curve of theophylline 149 
4.8 A chromatogram for the limit of quantification of theophylline 62.5 
ng/ml: peak (1) theophylline; peak (2) β-hydroxyethyltheophylline 
(the internal standard) 
 
154 
5.1 Chemical structures of major theophylline metabolites 165 
5.2 The HPLC system used 171 
5.3 Chromatogram of (A) blank urine, and (B) blank urine spiked with 1-
MU (10 µg/mL) (1), 3-MX (10 µg/mL) (2), 1,3-DMU (20 µg/mL)  (3), 
theophylline (10 µg/mL) (4) and the internal standard β-
hydroxyethyltheophylline (5) 
 
177 
5.4 Chromatogram of aqueous solutions of 1-MU (5 µg/mL) (1), 3-MX (5 
µg/mL) (2), 1,3-DMU (10 µg/mL) (3), theophylline (5 µg/mL) (4) and 
the internal standard β-hydroxyethyltheophylline (5) 
 
178 
5.5 Detector linearity for theophylline and its metabolites 180 
5.6 Mean standard calibration curves of theophylline and its metabolites 
in urine 
 
182 
5.7 A chromatogram for the limit of quantification of 1-MU (1), 3-MX (2), 
1,3-DMU (3), Theophylline (4) and the internal standard β-
hydroxyethyltheophylline (5) 
    
187 
5.8 Chromatgraphic separation of 1-MU (1), 3-MX (2), 1,3-DMU 
(3),Theophylline (4) and the internal standard (5) using long C18 
column 
 
191 
 XVII
6.1 Chromatograms of plasma sample obtained from a volunteer at 0.25 
hour after theophylline administration alone (A) and coadministered 
with ciprofloxacin (B) 
 
209 
6.2 Chromatogram of urine sample of theophylline and its major 
metabolites obtained from a volunteer after theophylline 
administration alone (A) and coadministration of  theophylline and 
ciprofloxacin (B) 
 
210 
 
 
6.3 Chromatogram of plasma sample obtained from a volunteer at 1 
hour after ciprofloxacin administration  
 
211 
6.4 Mean (± SD) plasma concentrations of theophylline (250-mg p.o) 
versus time profiles given alone or in combination with ciprofloxacin 
(500-mg twice daily p.o) after pretreatment with ciprofloxacin for 3 
days (N =9) 
 
217 
6.5 Theophylline plasma concentration versus time plot for volunteers 1 
and 2 
 
221 
6.6 Theophylline plasma concentration versus time plot for volunteers 3 
and 4 
 
222 
6.7 Theophylline plasma concentration versus time plot for volunteers 5 
and 6 
 
223 
6.8 Theophylline plasma concentration versus time plot for volunteers 7 
and 8 
 
224 
6.9 Theophylline plasma concentration versus time plot for volunteer 9 225 
6.10 Mean (± SD) plasma concentrations of ciprofloxacin versus time 
profiles given as single dose (500-mg p.o) or in multiple doses (500-
mg twice daily p.o for three days) n =9 
 
231 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XVIII
LIST OF ABBREVIATION 
 
 
Ah receptor 
 
aryl hydrocarbon receptor 
 
ANOVA 
 
analysis of variance 
 
AUC0-t area under plasma drug concentration-time curve up to t hours 
 
AUC0-∞ 
 
area under drug concentration-time curve from time 0 to infinity 
 
CAR 
 
constitutive androstane receptor 
 
CI 
 
confidence interval 
 
CLm formation clearance of metabolite 
 
CLo total body clearance 
 
CLR renal clearance 
 
Cmax 
 
Peak plasma concentration 
CV 
 
coefficient of variation 
 
CYP 
 
cytochrome P450 
1,3-DMU 
 
1,3-dimethyluric acid 
 
FDA Food and Drug Administration 
 
fm molar urinary recovery of the respective metabolite 
 
fe cumulative fraction of dose excreted in urine 
 
FMN flavin mononucleotide 
 
FAD flavin adenine dinucleotide 
 
FMO flavin monooxygenase 
 
GST glutathione-S-transferase 
 
HPLC 
 
high-performance liquid chromatography 
 
ke elimination rate constant 
 
 XIX
Ki inhibition constant 
 
Km Michaelis-Menten constant 
 
MI Metabolic intermediate 
 
mRNA 
 
messenger ribonucleic acid 
 
1-MU 1-methyluric acid 
 
3-MX 3-methylxanthine 
 
NS 
 
not statistically significant 
 
PAH 
 
polycyclic aromatic hydrocarbon 
 
P-gp 
 
P-glycoprotein 
 
pKa 
 
negative logarithm of acid ionization constant 
 
PPAR peroxisome proliferator-activated receptor 
 
PXR pregnane X receptor 
 
RXR retinoid X receptor 
 
SD 
 
standard deviation 
SEM standard error of the mean 
 
SNP single nucleotide polymorphism 
 
SULT 
 
sulfotransferase 
 
t1/2 elimination half life 
 
Tmax time at which highest concentration occurs 
 
UDP 
 
Uridine-diphosphate 
 
UGT 
 
UDP-glucuronosyltransferase 
 
Vd Volume of distribution 
 
Vmax maximum velocity of metabolism 
 
 
 XX
LIST OF EQUATIONS 
 
               Page 
 
1.1  19 
1.2  38 
2.1  74 
2.2  74 
3.1  105 
3.2  105 
3.3  106 
6.1  206 
6.2  206 
6.3  206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XXI
LIST OF APPENDICES 
 
          Page 
 
2.1 Calibration curve for freeze and thaw stability of ciprofloxacin (R2 
= 1) 
 
284 
2.2 Freeze and thaw stability of ciprofloxacin  285 
2.3 Calibration curve for stability study of ciprofloxacin  (R2 = 1) 286 
2.4 Stability of ciprofloxacin on long storage 287 
3.1 Volunteer information sheet and informed consent form 288 
3.2 Plasma Ciprofloxacin HCl concentration of volunteers after  
dosing with one tablet of Ciprobay® 500 mg for volunteers 1 to 12 
 
291 
3.3 Plasma Ciprofloxacin HCl concentration of volunteers after 
dosing with one tablet of Ciprobay® 500 mg for volunteers 13 to 
24 
 
292 
3.4 Plasma Ciprofloxacin HCl concentration of volunteers after 
dosing with one tablet of Enoxin® 500 mg  for volunteers 1 to 12 
 
293 
3.5 Plasma ciprofloxacin HCl concentration after dosing with one 
tablet of Enoxin® 500 mg for volunteers 13 to 24 
 
294 
3.6 Plasma concentration versus time profiles for volunteers 1 to 6 295 
3.7 Plasma concentration versus time profiles for volunteers 7 to 12 296 
3.8 Plasma concentration versus time profiles for volunteers 13 to 18 297 
3.9 Plasma concentration versus time profiles for volunteers 19 to 24 
 
298 
3.10 ANOVA Table of t 1/2  Values 299 
3.11 ANOVA Table of ke  Values 299 
4.1 Calibration curve for freeze and thaw stability of theophylline (R2 
= 0.9999) 
 
300 
4.2 Freeze and thaw stability of theophylline 301 
4.3 Calibration curve for Stability study of theophylline (R2 = 1) 302 
4.4 Stability of theophylline on long storage 303 
6.1 Subject information sheet 304 
6.2 Volume of urine collected for the individual volunteers 
(theophylline alone phase) over 48 hours 
 
308 
 XXII
6.3 Volume of urine collected for the individual volunteers 
(theophylline + ciprofloxacin phase) over 48 hours 
308 
6.4 Laboratory investigation values for all the healthy volunteers 309 
6.5 Auto-sampler stability of theophylline plasma samples 310 
6.6 Auto-sampler stability of theophylline and its metabolites in urine 
samples 
 
310 
6.7 Plasma theophylline concentration after dosing with two tablets of 
Nuelin® 125 mg for  all volunteers 
 
311 
6.8 Plasma theophylline concentrations after dosing with two tablets 
of Nuelin® 125 mg when coadministered with Ciprobay® for all 
volunteers 
 
312 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XXIII
KAJIAN-KAJIAN FARMAKOKINETIK SIPROFLOKSASIN DAN TEOFILIN 
SERTA INTERAKSI ANTARA KEDUA DRUG INI DALAM SUKARELAWAN 
MALAYSIA YANG SIHAT 
 
ABSTRAK 
 
Teofilin adalah sejenis bronkodilator yang kerap kali digunakan sebagai rawatan 
untuk penyakit asma dan halangan pernafasan kronik. Di dalam manusia dewasa, 
lebih kurang 90% teofilin dimetabolismekan di hati oleh enzim sitokrom P450 
(CYP), dan hanya 10% dikumuhkan melalui ginjal dalam bentuk asal. Tujuan 
kajian ini adalah untuk mengkaji interaksi farmakokinetik di antara regimen 
berganda dos oral siprofloksasin dengan teofilin dos tunggal dan menjelaskan 
mekanisme interaksinya di dalam sukarelawan-sukarelawan lelaki sihat. Untuk 
mencapai matlamat ini, kaedah HPLC yang sensitif dan selektif dengan pengesan 
lampau ungu telah dibangunkan dan disahkan untuk menentukan kepekatan 
siprofloksasin di dalam plasma dan kepekatan teofilin di dalam plasma dan urin.  
Koefisi variasi untuk kepersisan dan kejituan siprofloksasin kurang  daripada 7.8% 
melebihi julat kepekatan 50 hingga  5500 ng/mL dengan had pengesanan 25 
ng/mL. Keluk penentukuran  untuk teofilin di dalam plasma adalah linear (R² = 
0.9999) dalam julat kepekatan 62.5 hingga 20000 ng/mL bagi had pengesanan 
31.2 ng/mL. Koefisi variasi kepersisan dan kejituan untuk intra-hari dan antara hari  
kurang daripada 7.1%. Purata keseluruhan pemulihan untuk teofilin dan tiga 
metabolitnya di dalam urin berjulat daripada 85 hingga 102%. Had pengesanannya 
adalah 0.625 µg/mL untuk I-MU (asid 1- metilurik), 3-MX (3-metilxantin) dan teofilin 
dan  1.25 µg/mL untuk 1,3-DMU (asid 1,3-dimetilurik). Koefisi variasi intra-hari dan 
antara hari adalah kurang daripada 8.70%. Sejumlah sembilan orang sekarelawan 
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lelaki yang sihat telah mengambil bahagian di dalam kajian interaksi farmakokinetik 
ini. Kajian ini dijalankan secara rawak, label terbuka, dos tunggal, berpuasa dan 
kaedah bersilang tiga. Sukarelawan-sukarelawan ini dibahagikan secara rawak 
kepada tiga kumpulan dengan menerima tablet siprofloksasin sahaja, teofilin 
sahaja dan kombinasi siprofloksasin dan teofilin dalam semasa tempoh pertama 
kajian. Selepas seminggu tempoh pembersihan para sukarelawan menerima 
rawatan silang yang lain semasa tempoh kajian kedua dan ketiga yang juga 
dipisahkan selama seminggu tempoh pembersihan. Di dalam kajian gabungan, 
rawatan awal dengan siprofloksasin 500 mg setiap 12 jam untuk enam dos diikuti 
dengan dos tunggal 250 mg teofilin. Purata parameter farmakokinetik 
dibandingkan menggunakan ujian pelajar t-berpasangan. Keputusan kajian ini 
menunjukkan bahawa rawatan awal dengan siprofloksasin secara signifikan 
meningkatkan purata AUC0-∞, kepekatan plasma puncak (Cmax) dan separuh 
hayat(t 1/2 ) teofilin sebanyak 33.64% (P < 0.001), 15.23% (P < 0.004) dan 16.25% 
(P < 0.034), masing-masing dibandingkan dengan rawatan teofilin sahaja. 
Siprofloksasin juga dikenalpasti mengurangkan klearans keseluruhan teofilin 
sebanyak 27% (P < 0.001). Tambahan pula, keputusan kajian ini menunjukkan 
bahawa klearans ginjal pembentukan metabolit teofilin  ; 1-MU, 3-MX dan  1,3-
DMU masing-masing menurun secara signifikan (54.13%, 53.18% dan 34.98%). 
Kajian ini juga menyatakan bahawa siprofloksasin secara signifikan meningkatkan 
AUC0-∞ dan kepekatan plasma teofilin melalui perencatan CYP1A2 yang 
diperantarakan oleh metabolisme pengoksidaan secara in vivo. Berdasarkan 
penemuan kajian ini, adalah amat disarankan agar paras  serum harus sentiasa 
dipantau rapi apabila ubat ini diberikan bersama dengan siprofloksasin di dalam 
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amalan klinikal. Tambahan kepada kajian interaksi ini, kajian secara in-vivo yang 
lain dijalankan untuk menilai keperolehan bandingan antara Enoxin® dan 
Ciprobay® di dalam para sukarelawan lelaki sihat. Tiada perbezaan yang signifikan 
didapati berdasarkan analisis varian (ANOVA); pada 90% selang keyakinan nilai 
purata untuk nisbah ujian/rujukan adalah masing-masing  0.96 hingga 1.11 untuk 
AUC0-t dan 0.97 hingga 1.10 untuk AUC0-∞, manakala Cmax adalah 0.93 hingga 
1.07. Adalah disimpulkan bahawa kedua-dua formulasi ini mempunyai 
biokesetaraan yang saling boleh disilihgantikan. 
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PHARMACOKINETIC STUDIES OF CIPROFLOXACIN AND THEOPHYLLINE 
AND OF THE INTERACTION BETWEEN THESE TWO DRUGS IN HEALTHY 
MALAYSIAN VOLUNTEERS 
 
 
ABSTRACT 
 
 
Theophylline is a bronchodilator frequently used in the treatment of asthma and 
chronic obstructive pulmonary disease. In human adults, approximately 90% of 
theophylline is metabolised in the liver by the cytochrome P450 (CYP) enzymes, 
and only 10% is excreted via the kidneys in unchanged form. The aims of this work 
were to investigate the pharmacokinetic interaction between a multiple-dose 
regimen of oral ciprofloxacin and single dose of theophylline and to elucidate the 
mechanism of such interaction in healthy male volunteers. To achieve these aims, 
sensitive and selective HPLC methods with ultraviolet detection have been 
developed and validated for the determination of ciprofloxacin in plasma and 
theophylline in plasma and urine. The coefficient of variation for ciprofloxacin 
precision and accuracy was less than 7.8% over the concentration range of 50 to 
5500 ng/mL and with limit of detection of 25 ng/mL. The calibration curve for 
theophylline in plasma was linear (R² = 0.9999) in the concentration range of 62.5 
to 20000 ng/mL with a detection limit of 31.2 ng/mL. The coefficient of variation for 
intra-day and inter-day precision and accuracy was found to be less 7.1%. The 
overall mean recoveries for theophylline and its three metabolites in urine ranged 
from 85 to 102%. The detection limit was 0.625 µg/mL for I-MU (1-methyluric acid), 
3-MX (3-methylxanthine) and theophylline and 1.25 µg/mL for 1,3-DMU (1,3-
dimethyluric acid). The intra-day and inter-day coefficient of variation was less than 
8.70%. A total of nine healthy male volunteers participated in the pharmacokinetic 
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interaction study. This study was a randomised, open label, single-dose, fasting 
and three way crossover design. The volunteers were randomly divided into three 
groups and received ciprofloxacin alone, theophylline alone and combination of 
ciprofloxacin and theophylline tablets in the first period of the study. After a one-
week washout period the volunteers received the other crossover treatments 
during the second and third period which were separated also by a one-week 
washout period. In the combination study, pretreatment with ciprofloxacin 500 mg 
every 12 hr for six doses was followed by a single dose of 250 mg theophylline. 
Mean pharmacokinetic parameters were compared by the use of a student paired 
t-test. The results of the study indicated that pretreatment with ciprofloxacin 
significantly increased the average AUC0-∞, the peak plasma concentration (Cmax) 
and the t 1/2 of theophylline by 33.64% (P < 0.001), 15.23% (P < 0.004) and 16.25% 
(P < 0.034), respectively compared to the treatment by theophylline alone. 
Ciprofloxacin also markedly reduced the total clearance of theophylline by 27% (P 
< 0.001). Furthermore, our results showed that the renal clearances of theophylline 
metabolites formed; 1-MU, 3-MX and 1,3-DMU were significantly decreased 
(54.13%, 53.18% and 34.98%,  respectively). This study revealed that ciprofloxacin 
significantly raised the AUC0-∞ and the plasma concentration of theophylline by 
inhibiting its CYP1A2 mediated oxidative metabolism in vivo. Based on the findings 
of this study, it is strongly recommended that the serum level of theophylline should 
be closely monitored whenever this drug is used concomitantly with ciprofloxacin in 
clinical practice. In addition to the interaction study another in-vivo study was 
performed to evaluate the comparative bioavailability between Enoxin® and 
Ciprobay® in 24 healthy male volunteers. No significant difference was found 
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based on analysis of variance (ANOVA); the 90% confidence intervals of the mean 
values for the test/reference ratios were 0.96 to 1.11 for AUC0-t and 0.97 to 1.10 for 
AUC0-∞ respectively, while that of Cmax was 0.93 to 1.07. It was concluded that both 
formulations are bioequivalent and thus interchangeable.           
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CHAPTER 1  
 
INTRODUCTION 
 
 
1.1 PRINCIPLES OF DRUG METABOLISM  
Humans are exposed daily to a wide types of foreign compounds called 
xenobiotics ie. substances absorbed through the lungs or skin or ingested either 
inadvertently as those present in food and drink or deliberately as drugs for 
therapeutic purposes (Katzung, 2001a). These xenobiotics, including drugs, are 
eliminated from the body by several means. Most of pharmacologically active 
compounds are lipophilic which enables them to pass through biological 
membranes. These lipophilic compounds need to be biotransformed into more 
water soluble metabolites in order to be excreted into urine or bile (Meyer, 
1996). This biotransformation is catalyzed in humans by a number of drug 
metabolizing enzymes. Metabolites formed are often less active than the parent 
drug or even inactive, but the metabolites may also show enhanced 
pharmacological activity. In addition, the metabolism of drugs can produce 
harmful and toxic products which may be responsible for various forms of 
toxicity such as hepatotoxicity (Nelson et al., 1996).   
 
Liver is the major organ for drug biotransformation (Meyer, 1996), but 
drug-metabolizing enzymes are also present at other sites, such as the 
intestinal wall, kidney, lung and skin (Krishna and Klotz, 1994). One major 
enzyme system involved in drug biotransformation is the cytochrome P450 
(CYP) monooxygenase system. Other important enzymes include esterases, 
epoxide hydrolase and conjugating enzymes such as glucuronosyltransferases 
and sulfontransferases. 
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Drug metabolism is normally divided into two phases; functionalisation 
(phase I) and conjugation (phase II) reactions, respectively (Gibson and Skett, 
2001). Phase I reactions refer to a set of reactions that result in relatively small 
chemical changes that make compounds more hydrophilic and also provide a 
functional group that is used to complete the phase II reactions. The phase I 
reactions are mostly oxidative, incorporating a functional molecule such as a 
hydroxyl (-OH) group into the drug molecule (Meyer, 1996). Generally, they 
render the compound less lipophilic, but additionally serve to expose reactive 
sites, or to add functionally reactive sites to which polar groups may be 
conjugated. Oxidative metabolism represents a major route of elimination for 
many drugs (Lin and Lu, 1998). Other types of phase I reactions are reduction 
such as nitro reduction (chloramphenicol) and hydrolysis. Hepatic and 
extrahepatic CYP enzymes play a major role in phase I human drug metabolism. 
Functionalization reactions of phase I are reactions, which generate functional 
group as in hydroxylation or unmask functional group as in ester hydrolysis.  
 
There are also non-CYP450 oxidations, for example, monoamine 
oxidase reactions, different mechanism with the same result as P450 
deamination; flavin monooxygenase reactions (FMO), but P450 reductases also 
use flavin as flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) 
(Yan and Caldwell, 2001). Phase II reactions usually conjugate the drug with 
endogenous substrates, such as a glucuronide, glutathione or a sulfate group. 
Compounds that remain in the circulation after phase I metabolism often 
undergo phase II metabolism. Phase II reactions are characterized by 
conjugation with small endogenous substance, often taking advantage of 
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functional group added in phase I. The phase II conjugation reactions involve 
glucuronidation, sulphation, acetylation and conjugation with glutathione. The 
conjugated metabolites are highly water soluble and are readily excreted into 
urine and bile, which are the main routes of elimination for most drugs (Meyer, 
1996). Phase II enzymes that catalyse conjugation reactions include broad 
specificity transferases such as UDP-glucuronosyltransferases (UGT), 
glutathione-S-transferases (GST) and sulfotransferases (SULT). Many drugs 
undergo both phase I and phase II metabolism sequentially, but some can be 
excreted after either phase I or phase II reactions or even while still 
nonmetabolized (Krishna and Klotz, 1994). 
 
1.2 CYP ENZYMES  
 The CYP enzymes are a superfamily of heme-containing mono-
oxygenases (Wrighton and Stevens, 1992; Meyer, 1996). CYP 450 enzymes 
are so called because the pigment (P) has a 450 nm spectral peak when 
reduced and bound to carbon monoxide (Omura and Sato, 1962). CYP 
enzymes are found not only in human beings but also in bacteria, fungi, plants 
and animals (Nelson, 1999). Originally, CYP was thought to be a single enzyme, 
and by the mid-1960s, it was associated with drug and steroid metabolism. After 
advances in messenger ribonucleic acid (mRNA) purification in the early 1980s, 
cloning studies have revealed dozens of different CYP enzymes (Nebert and 
Russell, 2002), which comprise a superfamily of heme-thiolate proteins, and are 
found in every class of organism. This superfamily is believed to have originated 
from an ancestral gene that existed over three billion years ago. They are 
membrane-bound, localised to the smooth endoplasmic reticulum of the cells 
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(Meyer, 1996), and are responsible for most of the oxidative metabolism of both 
xenobiotics and endogenous substrates (Dresser et al., 2000; Lin and Lu, 1998).  
  
The nomenclature of all CYP enzymes is based on their amino acid 
sequence (Nelson, 1996). The CYP enzymes within the same family are 
designated by an Arabic numeral (e.g., CYP1) and share more than 40% 
identity in the amino acid sequence. The families are further divided into 
subfamilies, with enzymes within a subfamily designated by a capital letter (e.g., 
CYP1A) and sharing more than 55% identity in the amino acid sequence. 
Finally, an Arabic numeral after the letter denotes each individual isoenzyme 
(e.g., CYP1A2) (Nebert and Russel, 2002).  
 
 Functionally, the CYP enzymes are divided into two major classes, those 
with a specific role for example, in steroid biosynthesis, bile and arachidonic 
acid metabolism (CYP4, CYP5 and higher) and those essentially involved in the 
metabolism of xenobiotics such as drugs, anti-oxidants and chemicals (CYP1, 
CYP2, CYP3) (Nelson, 1999). Many of these enzymes are involved in 
metabolism of different substrates such as endogenous compounds, chemicals 
and natural plant products (Nelson et al., 1996). Among the 18 CYP gene 
families in humans recognised by Nelson in 1999, only the first three families 
(CYP1, CYP2, and CYP3) seem to be important in drug metabolism (Wrighton 
et al., 1996). The estimated proportions of the major drug metabolising CYP 
enzymes in human liver are as follows; CYP3A4 29%, CYP2C8 19%, CYP2E1 
19%, CYP1A2 15%, CYP2C9 12%, CYP2D6 3%, CYP2C19 2%, and CYP2B6 
< 1% (Pelkonen et al., 1998, Proctor et al., 2004). However, there are notable 
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interindividual differences in the hepatic contents of the different CYP enzymes. 
Furthermore, the hepatic abundance of the CYP enzymes does not correlate 
with the importance of the individual enzyme in drug metabolism. For example, 
CYP2D6 metabolises more than 75 different drugs (Nebert and Russell 2002), 
but CYP2E1 metabolises relatively few drugs. Together these enzymes account 
for approximately 70% of the total CYP hepatic content (Shimada et al., 1994). 
They are distinguished by their different substrate specificities and turnover 
capacities. Examples of substrates, inhibitors and inducers of these individual 
isoenzymes are presented in Table 1.1.  
 
 The expression and catalytic activity of CYP enzymes may vary greatly 
between individuals, due to genetic, non-genetic endogenous (e.g. diseases) 
and environmental (drugs, diet) factors (Pelkonen et al., 1998). Genetic 
polymorphism in drug metabolism greatly affects the activity of some CYP 
enzymes such as CYP2C19 and CYP2D6 (Nakamura et al., 1985; Wrighton et 
al., 1996). Some CYP enzymes are inducible by environmental factors such as 
drugs (Wrighton et al., 1996; Pelkonen et al., 1998). Furthermore, catalytic 
activity of CYP enzymes can be inhibited or inactivated.  
 
Induction and inhibition of CYP enzymes increase the intraindividual and 
interindividual variability of drug metabolism. The activity of certain CYP 
enzymes, for example CYP2D6, CYP2C9, CYP2C19 is mainly monogenically 
determined, with a fraction of the population having reduced or no enzyme 
activity due to any of several mutations in the gene coding for that enzyme 
(Tanaka, 1999). This phenomenon is termed genetic polymorphism and is 
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defined as the presence of different alleles at a certain gene locus with a 
frequency in the population over 1%, resulting in at least two genotypes in the 
population.  
 
Table 1.1 Examples of substrates, inhibitors and inducers of the main 
human hepatic drug-metabolising CYP enzymes. Modified from Bertz and 
Granneman (1997) and Pelkonen et al. (1998).  
 
Isozyme Substrates Inhibitors Inducers 
CYP1A2 Caffeine, Clozapine, 
Imipramine 
Olanzapine, Ropivacaine 
Theophylline, Tizanidine 
Cimetidine, Ciprofloxacin 
Fluvoxamine, Furafylline 
Rofecoxib 
Carbamazepine 
Charcoal grilled meat 
Cigarette smoke 
Omeprazole 
CYP2C8 Carbamazepine 
Ibuprofen, Paclitaxel 
Rosiglitazone, Tolbutamide 
Gemfibrozil 
Trimethprim 
Montelukast 
Phenobarbital 
Rifampicin 
CYP2C9 Glibenclamide 
Glipizide, Ibuprofen 
Losartan, Phenytoin 
S-Warfarin, Tolbutamide 
Amiodarone 
Fluconazole, Miconazole 
Sulfaphenazole 
Phenobarbital 
Rifampicin 
CYP2C19 Citalopram, Diazepam 
Proguanil 
Proton pump inhibitors 
S-Mephenytoin 
Clarithromycin 
Fluconazole 
Fluvoxamine, 
Omeprazole 
Phenobarbital 
Rifampicin 
CYP2D6 Amitriptyline, Fluvoxamine 
Fluoxetine, Haloperidol 
Metoprolol, Ondansetron 
Tramadol 
Flecainide, Fluoxetine 
Quinidine, Paroxetine 
Unknown 
CYP3A4 Alprazolam, Amiodarone 
Cyclosporin, Lovastatin 
Midazolam, Nifedipine 
Tacrolimus, Triazolam 
Clarithromycin 
Erythromycin 
Grapefruit juice 
Itraconazole 
Carbamazepine 
Phenobarbital 
Phenytoin 
St John’s wort 
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1.2.1 CYP1A SUBFAMILY  
CYP1A1 and CYP1A2 are the two members of the CYP1A subfamily. 
CYP1A1 is expressed mainly in extrahepatic tissue such as lungs, small 
intestine and placenta, and is of little importance in drug metabolism (Miners 
and McKinnon, 2000). There is genetic polymorphism in the inducibility of 
CYP1A1 by polycyclic aromatic hydrocarbons, with a high inducibility phenotype 
being more common in patients with lung cancer (Kouri et al., 1982; Nebert et 
al., 1991). CYP1A2 is abundantly expressed in the human liver, and it can also 
be expressed in some extrahepatic tissues, such as the gastrointestinal tract 
(Ding and Kaminsky, 2003). CYP1A2 enzyme metabolizes many commonly 
used drugs and this is the only isoenzyme affected by tobacco. In humans, the 
interindividual variability of the expression of CYP1A2 is large. For example, 
about 40-60 fold differences between different ethnic groups have been 
reported (Shimada et al., 1994).  
 
CYP1A2 metabolises, for example, caffeine, tacrine, clozapine, 
ropivacaine, theophylline, lidocaine and melatonin (Butler et al., 1989; Madden 
et al., 1993; Bertilsson et al., 1994; Oda et al., 1995; Tjia et al., 1996; Wang et 
al., 2000; Härtter et al., 2001). The major route of caffeine metabolism in man 
(N-3-demethylation of caffeine to paraxanthine) is mediated by CYP1A2 (Lelo et 
al., 1986; Butler et al., 1989). Therefore, caffeine is often used as a probe 
substrate for CYP1A2. For example, the caffeine/paraxanthine ratio is a suitable 
index of CYP1A2 activity in vivo (Fuhr and Rost, 1994). CYP1A2 is inhibited by, 
for example, fluvoxamine and ciprofloxacin (Nemerof et al., 1996; Fuhr et al., 
1992), and induced by cigarette smoking and other compounds containing 
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polycyclic aromatic hydrocarbons (PAH) and cruciferous vegetables. CYP1A 
enzymes transform some procarcinogens, such as PAH compounds and 
aflatoxin B1, to carcinogens (Miners and McKinnon, 2000).  
 
CYP1A2 activity shows interindividual variability which seems to be 
explained by both genetic and environmental factors (Rasmussen et al., 2002, 
Aklillu et al., 2003). Even though there is genetic polymorphism in the CYP1A2 
gene (www.imm.ki.se/CYPalleles/cyp1a2.htm), no nucleotide differences which 
can clearly explain the phenotypic variability in CYP1A2 gene expression or 
inducibility have been identified. A single nucleotide polymorphism (SNP), 
164C>A, the allele CYP1A2*1F, has been associated with higher inducibility of 
CYP1A2 activity (Chida et al., 1999, Sachse et al., 1999, Bondolfi et al., 2005), 
but this has not been confirmed in all studies (Schulze et al., 2001, Nordmark et 
al., 2002, Shimoda et al., 2002, Kootstra-Ros et al., 2005).  
 
1.2.2 CYP2B6  
The expression of CYP2B6 in human liver, and its role in hepatic drug 
clearance, has earlier been considered to be rather insignificant (Mimura et al., 
1993; Shimada et al., 1994). However, recent studies have suggested higher 
abundance of hepatic CYP2B6 with significant interindividual variability (Gervot 
et al., 1999; Hesse et al., 2000). Substrates of CYP2B6 are, for example, 
nevirapine, bupropion, propofol and ketamine (Erickson et al., 1999; Hesse et 
al., 2000; Court et al., 2001; Hijazi and Boulieu, 2002). The activity of CYP2B6 
can be inhibited by fluvoxamine, sertraline, paroxetine, hormone replacement 
therapy, clopidogrel, and ticlopidine (Hesse et al., 2000, Palovaara et al., 2003; 
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Turpeinen et al., 2005) and induced by, for example, phenobarbital and 
cyclophosphamide (Gervot et al., 1999). The CYP2B6 gene is highly 
polymorphic and the CYP2B6*6 mutation may have clinical relevance as it 
increases the 4-hydroxylation of cyclophosphamide (Xie et al., 2003).  
 
1.2.3 CYP2C  
The human CYP2C subfamily isoforms are primarily hepatic, but they 
exist in the small intestine as well, and include CYP2C8, CYP2C9, CYP2C18, 
and CYP2C19. CYP2C18 does not seem to be clinically important. Paclitaxel is 
the prototypic substrate for CYP2C8, and trimethoprim and montelukast are its 
selective inhibitors (Rettie et al., 2000, Wen et al., 2002, Walsky et al., 2005). 
Substrates of CYP2C9 are, for example, S-warfarin and ibuprofen (Bertz and 
Granneman, 1997) and sulfaphenazole is a prototypic inhibitor (Rettie et al., 
2000). For CYP2C19, hydroxylation of S-mephenytoin is a prototypic reaction, 
and omeprazole can serve as a selective inhibitor (Ko et al., 1997; Pelkonen et 
al., 1998). Other substrates, inhibitors and inducers are given in Table 1.1. 
CYP2C9 and CYP2C19 exhibit genetic polymorphism, with clinical 
consequences (Goldstein, 2001).  
 
1.2.4 CYP2D6 
Even though the amount of CYP2D6 is rather low compared to, for 
example, CYP3A4 and CYP1A2 in human liver, it metabolises approximately 
30% of all drugs (Fromm et al., 1999). Codeine, fluoxetine, fluvoxamine and 
tramadol are some substrates of CYP2D6. CYP2D6 is inhibited by several 
agents, such as its own substrates fluoxetine and paroxetine (Belpaire et al., 
 10
1998). Quinidine is a selective inhibitor of CYP2D6 (Newton et al., 1995). 
CYP2D6 seems not to be inducible, in contrast to all other CYP enzymes 
involved in human drug metabolism (Zanger and Eichelbaum, 2000). CYP2D6 
is polymorphically expressed; approximately 7% of the Caucasians lack 
functional CYP2D6 enzyme, being poor metabolisers (PMs) (Mahgoub et al., 
1977; Alvan et al., 1990). In contrast, individuals with a duplicated or 
multiplicated CYP2D6 gene have very high CYP2D6 activity and are called 
ultrarapid metabolisers (UMs) (Johansson et al., 1993).  
 
1.2.5 CYP2E1 
This enzyme participates in the metabolism of only a few drugs, often 
forming toxic metabolites. Ethanol is both a substrate and inducer of CYP2E1 
(Klotz and Ammon, 1998). In addition, CYP2E1 metabolises paracetamol 
(acetaminophen), halothane, chlorzoxazone and mediates activation of many 
carcinogens (Klotz and Ammon, 1998; Raucy and Carpenter, 2000). 
 
1.2.6 CYP3A SUBFAMILY  
CYP3A4, CYP3A5 and CYP3A7 belong to the CYP3A subfamily and 
seem to have similar substrate specificities (Wrighton and Thummel, 2000). 
CYP3A7 is poorly expressed in the adult human liver, but in foetal human liver it 
accounts for 50% of all expressed CYP enzymes (Wrighton et al., 1988; Koch et 
al., 2002). 
 
CYP3A4 is one of the most important drug metabolising CYP enzymes in 
humans. In addition to the abundant expression of CYP3A4 in the liver 
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(approximately 30%), it is the dominant CYP enzyme in the small intestinal 
mucosa (Shimada et al., 1994; Kivistö et al., 1996; Zhang et al., 1999). It has 
been suggested that approximately 50% of all clinically used drugs that are 
metabolised are substrates of CYP3A4 (Table 1.1). Hepatic and intestinal 
CYP3A4 are induced by several drugs, for example rifampicin, carbamazepine, 
phenytoin, and St John`s wort (Hypericum Perforatum) (Backman et al., 1996a; 
Backman et al., 1996b; Pelkonen et al., 1998; Dürr et al., 2000). 
 
CYP3A5 is, in contrast to CYP3A4, polymorphically expressed (Kuehl et 
al., 2001). CYP3A5 can be found in significant levels in approximately 10-40% 
of Caucasians, 40-50% of Chinese and more than 50% of African Americans 
(Wrighton et al., 1990; Tateishi et al., 1999; Chou et al., 2001; Kuehl et al., 
2001).  
 
1.3 INHIBITION OF CYP ENZYMES  
 
Inhibition of CYP enzymes by xenobiotics, at certain concentrations, is 
often selective for a limited number of isoforms. For example, itraconazole is a 
potent and relatively selective inhibitor of CYP3A4 (Back and Tjia, 1991). The 
fluoroquinolone antibiotic ciprofloxacin inhibits mainly CYP1A2 (Bertz and 
Granneman, 1997) and paroxetine inhibits mainly CYP2D6 (Jeppesen et al., 
1996). Ki is an inhibition constant related to the affinity of a compound to an 
enzyme, and is important in predicting in vivo drug-drug interactions resulting 
from metabolic inhibition. Ki can be estimated in vitro either graphically by 
plotting methods or by nonlinear regression analysis. The mechanisms of CYP 
inhibition can be divided into reversible inhibition, quasi-irreversible and 
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irreversible inhibition, of which reversible inhibition is probably the most 
common (Lin and Lu, 1998). 
 
  Reversible inhibition can be further divided, based on enzyme kinetics, 
into competitive, noncompetitive, and uncompetitive. In competitive inhibition, 
the inhibitor competes with the substrate for the active site of the free enzyme, 
for example the CYP3A4 inhibitor itraconazole (Von Moltke et al., 1996). In 
noncompetitive inhibition, the inhibitor binds to a different binding site of the 
enzyme and has no effect on the binding of the substrate for example the 
inhibition of the CYP3A-catalysed conversion of dextrometorphan to 3-
methoxymorphinan by omeprazole, (Ko et al., 1997). In uncompetitive inhibition, 
the inhibitor binds only to an enzyme substrate complex, not to the free enzyme 
for example the CYP2E1 inhibitor cotinine (Van Vleet et al., 2001).  
 
 In quasi-irreversible inhibition, an inhibitor is first metabolically activated 
by the CYP enzyme, and then this inhibitory metabolite forms a stable metabolic 
intermediate (MI) complex with the prosthetic heme of CYP, rendering the 
enzyme functionally inactive. MI complexation can be reversed in vitro but not in 
vivo, hence, the name quasi-irreversible (Lin and Lu, 1998). Erythromycin is an 
example of a quasi-irreversible inhibitor of CYP3A (Thummel and Wilkinson, 
1998). 
 
 Additionally, in irreversible inhibition, a drug is oxidized by the CYP to a 
reactive intermediate, which covalently binds to the enzyme causing irreversible 
inactivation. This kind of inhibition is also called mechanism-based or suicide 
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inhibition (Lin and Lu, 1998; Thummel and Wilkinson, 1998). Mechanism-based 
inhibitors of CYP enzymes in vitro are, for example, furafylline (CYP1A2), 
gestodene (CYP3A4) and ethinylestradiol (CYP3A4) (Guengerich, 1990; Kunze 
and Trager, 1993; Lin and Lu, 1998). 
 
In quasi-irreversible and irreversible inhibition (MI complexation and 
mechanism-based inhibition), a time-dependent proportion of the CYP enzymes 
is complexed or destroyed, while the remaining enzymes show normal activity. 
This leads to a time-dependent decrease in Vmax (maximum velocity of 
metabolism) but no change in Km (Michaelis-Menten constant). Time-dependent 
loss of enzyme activity is one of the most important criteria in distinguishing 
between reversible and irreversible inhibition (Lin and Lu, 1998).  
 
1.4 INDUCTION OF CYP ENZYMES  
Induction is defined as an increase in amount and activity of a drug-
metabolizing enzyme, as a consequence of long-term (hours and days) 
chemical exposure (Pelkonen et al., 1998). From a biological point of view, 
induction is an adaptive response that protects the cells from toxic xenobiotics 
by enhancing the detoxification activity. However, induction may also enhance 
toxicity by increased formation of reactive metabolites (Lin and Lu, 1998). Many 
inducers are also inhibitors of the enzymes they induce, and the inductive 
effects of a single drug may be mediated by more than one mechanism (Fuhr, 
2000).  
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Some, but not all, CYP enzymes are inducible. The regulation of gene 
transcription generally depends on inducers interacting with certain receptors. 
The expression of CYP1 genes is induced by the cytosolic aryl hydrocarbon (Ah) 
receptor, which dimerizes with the Ah receptor nuclear translocator, in response 
to many polycyclic aromatic hydrocarbons such as those found in industrial 
incineration products, cigarette smoke, and charcoal grilled food (Nebert and 
Russell, 2002; Rushmore and Kong, 2002). After a sequence of events, the 
appropriate mRNA is transcribed and translated into its corresponding protein 
(Lin and Lu, 1998).   
 
The large interindividual variation in CYP1A inducibility is probably linked 
to genetic polymorphism in Ah receptor; studies suggest an increased risk for 
malignancies in individuals who have the high affinity Ah receptor phenotype 
(Miners and McKinnon, 2000). Sometimes the binding of inducing agents to the 
Ah receptor also leads to induction of phase II enzymes such as uridine 
diphosphate glucosyltransferases and glutathione-S-transferases (Lin and Lu, 
1998). 
 
Induction of CYP3A4 is mediated by nuclear receptors: pregnane X 
receptor (PXR), constitutive androstane receptor (CAR), and peroxisome 
proliferator-activated receptor (PPAR) (Waxman, 1999; Fuhr, 200; Gibson and 
Skett, 2001). In order to activate the CYP3A4 gene, PXR and CAR first have to 
bind to an inducer, and thereafter form heterodimers with the retinoid X receptor 
(RXR) which binds to specific gene regulation elements (Gibson and Skett, 
2001).  
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The rifampicin/glucocorticoid-type induction appears to be mediated by 
PXR, which is activated by CYP3A4 inducers such as rifampicin and 
phenobarbital (Fuhr, 2000; Goodwin et al., 2002). All CYP3A4 substrates are 
subject to this type of induction (Fuhr, 2000). Rifampicin is a potent inducer of 
CYP3A4 and found to reduce the AUC of oral midazolam, triazolam, and 
buspirone by > 90% (Backman et al., 1996a; Villikka et al., 1997; Backman et 
al., 1998; Lamberg et al., 1998).  
 
1.5 CYP INHIBITION AND INDUCTION IN DRUG-DRUG INTERACTIONS  
 
Drug interactions are always major concern in medicine and for the 
pharmaceutical industry. They can cause considerable differences in drug 
response and lead to adverse effects of drugs. Drug interactions can be 
pharmacokinetic or pharmacodynamic in nature, but pharmacokinetic 
interactions are more common. Pharmacodynamic interactions cause changes 
in the effects of drugs for example alcohol enhances the sedative effect of 
benzodiazepines (Seppälä et al., 1982). Pharmacokinetic interactions can take 
place at the level of drug absorption, distribution, metabolism and excretion. 
 
Environmental factors such as drugs, tobacco smoking, charcoal grilled 
meat, and grapefruit juice can inhibit or induce CYP enzyme. A change in drug 
metabolism is an important cause of pharmacokinetic drug-drug interactions 
(Dresser et al., 2000). The clinical significance of a drug-drug interaction 
depends on the magnitude of change in the active parent drug and/or active 
metabolite concentrations at the effect site, and on the therapeutic index of the 
drug. For example, anticoagulants, antidepressants, and cardiovascular drugs 
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have a narrow therapeutic index, making patients on these drugs more prone to 
drug interactions (Lin and Lu, 1998). Theophylline which was used as a 
substrate in this pharmacokinetic interaction study has a low therapeutic index. 
 
The administration route of the CYP substrate can influence the clinical 
effect of enzyme inhibition and induction, because orally administered drugs are 
exposed to the intestinal CYPs during absorption. For example, grapefruit juice 
greatly inhibits the CYP3A4 in the small intestine and thereby impairs the 
intestinal first-pass metabolism of orally administered CYP3A4 substrate drugs 
such as lovastatin (Kantola et al., 1998). On the other hand, itraconazole 
inhibits CYP3A4 both in the gut and the liver, impairing both the first-pass and 
systemic elimination of CYP3A4 substrates such as midazolam (Olkkola et al., 
1996). Rifampicin seems to induce more the intestinal than the hepatic CYPs 
(Hebert et al., 1992). 
 
1.6 DRUG TRANSPORTERS 
Transport processes are increasingly acknowledged as important 
determinants of absorption, distribution and excretion of drugs through cell 
membranes. It is often necessary to consider both metabolisms (by CYP 
enzymes) and transport mechanisms (by drug transporters) together when 
predicting in vivo pharmacokinetics (Kusuhara and Sugiyama, 2002).  
 
The main efflux transporter is P-glycoprotein (P-gp). P-gp is involved in 
the excretion of substances into the gut, bile, and urine, and is considered to 
play an important role in the blood brain, blood testes, and blood placenta 
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barriers (Lo and Burckart, 1999). P-gp has overlapping substrate specificity with 
CYP3A4 (for example diltiazem, nifedipine, HIV protease inhibitors) (Lin and 
Yamasaki, 2003). Recently, P-glycoprotein induction by rifampicin was shown to 
be mediated by the orphan nuclear receptor PXR (Geick et al., 2001), which is 
involved in CYP3A4 induction. 
 
 However, important exceptions exist: as an example, digoxin is 
eliminated almost entirely by excretion, but is a prototypical P-glycoprotein 
substrate susceptible to clinically relevant drug interactions with P-gp inhibitors 
such as itraconazole, verapamil, cyclosporine and quinidine (Partanen et al., 
1996; Fromm et al., 1999; Silverman, 2000). Another example, midazolam is a 
substrate of CYP3A4 but not of P-gp (Kim et al., 1999).  
 
It seems that intact P-gp activity is of special importance in preventing 
central nervous system (CNS) -adverse effects of drugs (Lin and Yamazaki, 
2003). Generally, P-gp inhibition leads to a much greater increase in drug 
concentrations in the brain than in plasma (Lin and Yamazaki, 2003). Healthy 
volunteers tolerated the P-gp substrate loperamide well when it was ingested 
with placebo, but when administered with the P-gp inhibitor quinidine, it caused 
respiratory depression (Sadeque et al., 2000).  
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1.7 BIOEQUIVALENCE AS A PROOF OF THERAPEUTIC EQUIVALENCE 
Generic drugs have been introduced on the pharmaceutical market 
mainly to reduce drug expenses by the consumers and health care authorities. 
This concern about lowering health care costs has resulted in a tremendous 
increase in the use of generic drug products. The term ‘generic product’ is used 
in different ways. It can mean a product marketed under the drug’s non-
proprietary approved name, or it can mean a product marketed under a different 
brand (proprietary) name. It is sometimes used to mean any product from a 
company other than the innovator (research-based) manufacturer. A common 
use of the term (and that used by the World Health Organization (WHO)), is for 
a pharmaceutical product that is intended to be interchangeable with the 
innovator product in an individual patient, usually manufactured without a 
licence from the innovator company marketed after expiry of patent or other 
exclusivity rights (Birkett, 2003). 
  
1.7.1 RELATIVE BIOAVAILABILITY 
Bioavailability is a pharmacokinetic term that describes the rate and 
extent to which the active drug ingredient is absorbed from a drug product and 
becomes available at the site of drug action. Since pharmacologic response is 
generally related to the concentration of drug at the receptor site, the availability 
of a drug from a dosage form is a critical element of a drug product's clinical 
efficacy. However, drug concentrations usually cannot be readily measured 
directly at the site of action. Therefore, most bioavailability studies involve the 
determination of drug concentration in the blood or urine. This is based on the 
premise that the drug at the site of action is in equilibrium with drug in the blood. 
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It is therefore possible to obtain an indirect measure of drug response by 
monitoring drug levels in the blood or urine. Thus, bioavailability is concerned 
with how quickly and how much of a drug appears in the blood after a specific 
dose is administered. The bioavailability of a drug product often determines the 
therapeutic efficacy of that product since it affects the onset, intensity and 
duration of therapeutic response of the drug. 
 
 Relative or comparative bioavailability refers to the availability of a drug 
product as compared to another dosage form or product of the same drug given 
in the same dose. These measurements determine the effects of formulation 
differences on drug absorption. The relative bioavailability of product A 
compared to product B, both products containing the same dose of the same 
drug, is obtained by comparing their respective area under the curves (AUCs). 
 
Relative Bioavailabilty = 
AUCB
AUCA                                                    (1.1) 
 
where drug product B is the reference standard. When the bioavailability of a 
generic product is considered, it is usually the relative bioavailability that is 
referred to.  
 
 Numerous biopharmaceutical studies have clearly indicated that the 
formulation and manufacture factors as well as the physicochemical properties 
of the drug can markedly affect the rate and extent of absorption of a drug. This 
led to the realization that different products of the same drug moiety containing 
the same molar dose may not necessarily be bioequivalent and achieve similar 
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drug concentrations in the plasma. Therefore, they may not be therapeutically 
equivalent.  
 
1.7.2 FACTORS AFFECTING BIOAVAILABILITY 
The various factors that can influence the bioavailability of a drug can be 
broadly classified as dosage form-related or patient-related. Some of the factors 
related to the physicochemical properties of the drug are particle size, 
crystalline structure, degree of hydration of crystal, salt or ester form of the 
formulation, amount of disintegrant and lubricant and nature of diluents. 
 
Particle size of a drug may markedly affect its dissolution rate and hence 
the absorption. Particle size can have a significant effect on AUC. This had 
been demonstrated by Neuvonen et al. (1977) after administration of equal 
doses containing micronized formulation and conventional formulation, serum 
levels of phenytoin were measured. Based on the AUC, almost twice as much 
phenytoin was absorbed after the micronized preparation. 
 
 The bioavailability of oral dosage forms decreases in the following order: 
solutions > suspensions > capsules > tablets > coated tablets (Hirst, 1976). 
Although this ranking is not universal, it does provide a useful guideline 
(Ashford, 2000a). On the other hand, the particular salt of a drug has been 
shown to affect the rate and extent of absorption. The oral hypoglycaemic 
tobutamide sodium is absorbed faster than that of the free acid (Ashford, 
2000a). 
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Another important factor to be considered is the crystal form of the drug. 
A classic example of the influence of polymorphism (more than one crystal 
form) on drug bioavailability is provided by chloramphenicol palmitate. The three 
polymorphs of chloramphenicol in suspensions resulted in different plasma 
levels (Aguiar, 1967). The chloramphenicol concentration in the body depended 
on the percentage of β-polymorph in the suspension. Generally, the crystal form 
that has the lowest free energy is the most stable polymorph (Shargel and Yu, 
2003). Differences in bioavailability may also occur between the anhydrous and 
hydrated forms of a drug. The anhydrous form of ampicillin was absorbed more 
than the slower dissolving trihydrate form (Ashford, 2000a). 
 
 In addition to some of the dosage form-related factors identified above, 
bioavailability may also be affected by a variety of physiological and clinical 
factors related to the patient. Considerable inter-subject differences in the bio-
availability of some drugs have been observed. These can often be attributed to 
individual variations in such factors as gastric emptying rate, intestinal transit 
time, intestinal absorptive capacity along the gastrointestinal tract, variations in 
pH of gastrointestinal fluids, disease states, food, fluid volume and other drugs 
(Chereson, 1999).  
 
Since the proximal small intestine is the optimum site for drug absorption, 
a change in the stomach emptying rate is likely to alter the rate, and possibly 
the extent of drug absorption. Any factor that slows the gastric emptying rate 
may thus prolong the onset time for drug action and reduce the therapeutic 
efficacy of drugs that are primarily absorbed from the small intestine. In 
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addition, a delay in gastric emptying could result in extensive decomposition 
and reduced bioavailability of drugs that are unstable in the acidic media of the 
stomach such as penicillins and erythromycin (Chereson, 1999).  
 
There are numerous factors that affect gastric emptying rate (Blanchard 
and Sawchuk, 1979). Factors such as a patient's emotional state, certain drugs, 
type of food ingested and even a patient's posture can alter the time course and 
extent of drug absorption (Nimmo et al., 1973; Blanchard and Sawchuk, 1979; 
Bennett et al., 1984; Ashrof, 2000b). The intestinal transit time is relatively 
constant and unaffected by food (Mundy et al., 1989; Ashrof, 2000b). On the 
other hand, the gastric emptying of pharmaceuticals is highly variable and is 
influenced by food (Davis et al., 1984; Ashford, 2000b).  
 
The escalating cost in health care has created a demand for cheaper 
drug products. As a consequence, many generic formulations of established 
products appeared in the market. Hence, bioequivalence assessment of generic 
drugs with innovator formulations is required in order to exclude any clinically 
significant difference in the rate and extent to which the active moiety becomes 
available at the site of drug action. Consequently, this will protect the consumer 
from any difference in activity of the generic as compared to the innovator.  
 
Two products are considered therapeutically equivalent if they contain 
the same active substance or therapeutic moiety, and show the same efficacy 
and safety clinically (EMEA, 2001). Establishing bioequivalence between two 
products in adequately designed bioequivalence studies is considered sufficient 
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proof of therapeutic equivalence and no further clinical evidence of therapeutic 
equivalence is needed. From the regulatory point of view this means that, two 
drug products are considered interchangeable if they contain the same active 
drug substance and have been shown to be bioequivalent (CDER, 2000; CDER, 
2001; EMEA, 2001). 
 
1.7.3 METHODOLOGY USED FOR THE EVALUATION OF  
           BIOEQUIVALENCE 
 According to current regulatory guidelines, bioequivalence studies should 
be designed in such a way that the effect of the formulation can be 
distinguished from other effects (EMEA, 2001). Basically, a bioequivalence 
study compares the systemic exposure of two drug products, commonly 
referred to as test (the new product) and reference (the existing product for 
which efficacy and safety have been shown). There are several test procedures 
that are considered adequate for the evaluation of bioequivalence. These 
include pharmacokinetic, pharmacodynamic, clinical, and in vitro studies. 
Pharmacokinetic bioequivalence studies are usually preferable (Chen et al., 
2001). 
 
For establishing pharmacokinetic bioequivalence between test and 
reference, the similarity of certain pharmacokinetic parameters for the products 
is evaluated as a measure of systemic exposure. The pharmacokinetic 
parameters to be determined for the test and the reference include AUC0-t, 
AUC0-∞, Cmax, tmax, Cmax / AUC, ke and t ½. Adequate parameters are chosen on 
clinical and pharmacokinetic grounds. Usually the primary parameters for the 
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evaluation of bioequivalence are Cmax and AUC. The study design has to reflect 
the pharmacodynamic and pharmacokinetic properties of the drug 
compound(s), i.e., one needs to consider how these properties relate for 
example to sampling times, wash-out periods, and active metabolites. In 
addition, several details of bioequivalence study designs are provided in 
regulatory guidelines (Malaysian Guidelines for the Conduct of Bioavailability 
and Bioequivalence Studies, 2000; CDER, 2000; EMEA, 2001). 
 
Bioequivalence studies are generally conducted in healthy male and 
female volunteers who are at least 18 years old, although they may also be 
carried out in target indication patients. Rather recently a requirement has been 
issued for conducting bioequivalence studies in a population that is 
representative of the population of patients who will use the drug (CDER, 2000). 
Thus, bioequivalence studies will increasingly be conducted also in the elderly. 
 
Three different methods may be used for the evaluation of 
pharmacokinetic bioequivalence. These methods comprise the evaluation of 
average, individual, and population bioequivalence. The average 
bioequivalence method remains the primary method for assessing 
bioequivalence in new regulatory guidelines for conducting and analysing 
bioequivalence studies (CDER, 2000; CDER, 2001; EMEA, 2001). 
 
1.7.4 AVERAGE BIOEQUIVALENCE 
Non-replicate study-designs: For the evaluation of average 
bioequivalence, a two period cross over study-design is usually considered 
